MedTrace Logo

Memantine in Adult Autism Spectrum Disorder

NCT01078844 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-07-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if memantine is helpful in managing problematic symptoms in adults with autism, Asperger's disorder, or Pervasive Developmental Disorder not otherwise specified (NOS).

Conditions

  • Autism
  • Asperger's Disorder
  • Pervasive Developmental Disorder NOS

Interventions

DRUG

memantine

memantine 5-20 mg daily

DRUG

Placebo

Look-alike placebo

Sponsors & Collaborators

Principal Investigators

  • Eric Samstad, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01078844 on ClinicalTrials.gov